Leonabio, Inc. · NASDAQ:LONA

Leonabio — Athira Pharma — Corporate Update (October 2022)

11 slides from Leonabio's corporate update, Oct 17, 2022

  1. Slide 1: Phase 2/3 LIFT-AD Interim Analysis Results and Next Steps

    Phase 2/3 LIFT-AD Interim Analysis Results and Next Steps October 17, 2022 Exhibit 99.2

  2. Slide 2: Forward-looking statements

    This presentation and the accompanying oral commentary contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our m

  3. Slide 3: Independent Unblinded Interim Analysis Supports Potential Clinically Meaningful Activity of Fosgonimeton

    Independent Unblinded Interim Analysis Supports Potential Clinically Meaningful Activity of Fosgonimeton WITHOUT BACKGROUND THERAPY and Mitigates Program Risk Phase 2 exploratory ACT-AD study results suggested congruent positive effects Cognition (ADAS-Cog11); Function (ADCS-ADL23); Neurodegeneratio

  4. Slide 4: Chief Medical Officer Hans Moebius, M.D., Ph.D

    Chief Medical Officer Hans Moebius, M.D., Ph.D © Athira Pharma, Inc. All Rights Reserved.

  5. Slide 5: Summary of Phase 2 ACT-AD Study Results

    Exploratory study to inform larger LIFT-AD in Patients without background therapy Summary of Phase 2 ACT-AD Study Results ADAS-Cog11, Alzheimer's Disease Assessment Scale–Cognitive Subscale; ADCS-ADL23, Alzheimer's Disease Cooperative Study–Activities of Daily Living; ERP, event related potential; N

  6. Slide 6: Learnings from ACT-AD Inform Study Design Optimization

    LEARNINGS FROM ACT-AD INFORM STUDY DESIGN OPTIMIZATION Fosgonimeton Phase 2/3 LIFT-AD Study Design POPULATION TREATMENT DURATION RESULTS LIFT-AD: Target N=TBD, informed by interim analysis Mild-to-moderate AD subjects 55-85 years CDR 1 and 2 MMSE 14-24 Approximately 40% of patients not on background

  7. Slide 7: Steps completed since ACT-AD Readout in June 2022

    Steps completed since ACT-AD Readout in June 2022 Additional analysis of ACT-AD DSMB unblinded adjudication of LIFT-AD Blinded analysis of LIFT-AD Proactively amended Phase 2/3 LIFT-AD in September Independent unblinded interim analysis in October Systematic and Data-driven Process to Support LIFT-A

  8. Slide 8: LIFT-AD Sample Size Well Powered for Primary Endpoint

    Stringent criteria applied to increase probability of demonstrating a clinically meaningful effect size for cognition and function LIFT-AD Sample Size Well Powered for Primary Endpoint *Mehta and Pocock, 2000, 2011 © Athira Pharma, Inc. All Rights Reserved. 0 +1 +2 +2.5 +3 +4 0 -1 -2 -2.5 -3 -4 ADAS

  9. Slide 9: President and Chief Executive Officer Mark Litton, Ph.D

    President and Chief Executive Officer Mark Litton, Ph.D © Athira Pharma, Inc. All Rights Reserved.

  10. Slide 10: Moving Forward

    Moving Forward © Athira Pharma, Inc. All Rights Reserved. *As of June 30, 2022 Target enrollment completion by mid 2023 with data in early 2024 Continued focus on LIFT-AD recruitment and completion to meet timelines Strong cash and cash equivalents of approximately $282M* provides support through ke

  11. Slide 11: Fosgonimeton – A New Potential Therapy for Alzheimer's Disease

    Fosgonimeton – A New Potential Therapy for Alzheimer’s Disease 35 million Estimated Alzheimer’s cases worldwide1 1 https://www.who.int/news-room/fact-sheets/detail/dementia 2 https://www.alz.org/media/documents/alzheimers-facts-and-figures.pdf 3 GlobalData AD prevalence data access and analysis 4 ht

Athira Pharma — Corporate Update (October 2022) on 6ix